NeuroOne Q2 product revenue up 72% to $2.4M; net loss narrows to $2.1M

NEUROONE MEDICAL TECHNOLOGIES Corp

2026-Q2 EPS reported -$0.44 revenue$5,283,820

Product revenue $2.4M (+72% YoY); no license revenue vs $3.0M in prior year first half.
Net loss $2.1M ($0.25/sh) vs $2.3M ($0.44/sh) in same quarter last year.
Cash $2.8M; working capital $5.7M; no debt outstanding; accounts receivable $2.4M.
16 trigeminal neuralgia cases completed with all patients reportedly pain free.
Christopher Volker to become CFO effective July 1, 2026; David Wambeke hired as CBO.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

NEUROONE MEDICAL TECHNOLOGIES Corp reported financial results for the fiscal quarter ended March 31, 2026.

Period: the fiscal quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 12, 2026, NeuroOne Medical Technologies Corporation (the "Company") issued a press release announcing its financial results for the fiscal quarter ended March 31, 2026.

View on SEC.gov

571 earnings releases filed in the last 30 days. Browse all earnings releases →

NEUROONE MEDICAL TECHNOLOGIES Corp filing history →

Source: SEC EDGAR

accession 0001213900-26-054744

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.